VERU Veru Inc. logo

VERU Veru Inc.

Healthcare
$2.35+5.86%ClosedMarket Cap: $37.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

1.46

P/S

0.00

EV/EBITDA

-0.46

DCF Value

$0.66

FCF Yield

-69.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-53.4%

ROA

-32.7%

ROIC

-73.1%

Financials

View All
PeriodRevenueNet IncomeEPS
Q2 null$0.00$-2.7M$
Q1 null$0.00$-5.3M$
Q4 null$0.00$1.3M$
FY null$0.00$-22.7M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$4.00

Target (Median)

$4.00

Target Range

$3.00 - $5.00

0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
OppenheimerOutperform
2026-05-15
Raymond JamesOutperform
2025-08-13

Trading Activity

Insider Trades

View All
STEINER MITCHELL SHUSTERdirector, officer: President and CEO
SellWed May 06
Rankowitz Michael Ldirector
SellWed May 06
Lu Lucydirector
SellWed May 06
Katzovitz Loren Markdirector
SellWed May 06
Hyun Gracedirector
SellWed May 06

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

-1.17

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Peers